211 related articles for article (PubMed ID: 19493342)
21. Von Hippel-Lindau disease and sporadic renal cell carcinoma.
Zbar B
Cancer Surv; 1995; 25():219-32. PubMed ID: 8718521
[TBL] [Abstract][Full Text] [Related]
22. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.
Rini BI; Jaeger E; Weinberg V; Sein N; Chew K; Fong K; Simko J; Small EJ; Waldman FM
BJU Int; 2006 Oct; 98(4):756-62. PubMed ID: 16827904
[TBL] [Abstract][Full Text] [Related]
23. [Heredity in renal and prostatic neoplasia].
Prayer Galetti T; D'Arrigo L; De Zorzi L; Patarnello T
Arch Ital Urol Androl; 1997 Sep; 69(4):241-6. PubMed ID: 9417296
[TBL] [Abstract][Full Text] [Related]
24. Genomic organization and chromosomal localization of the human CUL2 gene and the role of von Hippel-Lindau tumor suppressor-binding protein (CUL2 and VBP1) mutation and loss in renal-cell carcinoma development.
Clifford SC; Walsh S; Hewson K; Green EK; Brinke A; Green PM; Gianelli F; Eng C; Maher ER
Genes Chromosomes Cancer; 1999 Sep; 26(1):20-8. PubMed ID: 10441001
[TBL] [Abstract][Full Text] [Related]
25. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients.
Lubensky IA; Gnarra JR; Bertheau P; Walther MM; Linehan WM; Zhuang Z
Am J Pathol; 1996 Dec; 149(6):2089-94. PubMed ID: 8952541
[TBL] [Abstract][Full Text] [Related]
26. Three novel germ-line VHL mutations in Hungarian von Hippel-Lindau patients, including a nonsense mutation in a fifteen-year-old boy with renal cell carcinoma.
Losonczy G; Fazakas F; Pfliegler G; Komáromi I; Balázs E; Pénzes K; Berta A
BMC Med Genet; 2013 Jan; 14():3. PubMed ID: 23298237
[TBL] [Abstract][Full Text] [Related]
27. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.
Na X; Wu G; Ryan CK; Schoen SR; di'Santagnese PA; Messing EM
J Urol; 2003 Aug; 170(2 Pt 1):588-92. PubMed ID: 12853836
[TBL] [Abstract][Full Text] [Related]
28. Genetic evaluation of von Hippel-Lindau disease for early diagnosis and improved prognosis.
Akcaglar S; Yavascaoglu I; Vuruskan H; Oktay B
Int Urol Nephrol; 2008; 40(3):615-20. PubMed ID: 18074239
[TBL] [Abstract][Full Text] [Related]
29. No evidence for DNA methylation of von Hippel-Lindau ubiquitin ligase complex genes in breast cancer.
Huang KT; Dobrovic A; Fox SB
Breast Cancer Res Treat; 2010 Dec; 124(3):853-6. PubMed ID: 20680678
[TBL] [Abstract][Full Text] [Related]
30. Genetic and epigenetic alterations in the von hippel-lindau gene: the influence on renal cancer prognosis.
Smits KM; Schouten LJ; van Dijk BA; Hulsbergen-van de Kaa CA; Wouters KA; Oosterwijk E; van Engeland M; van den Brandt PA
Clin Cancer Res; 2008 Feb; 14(3):782-7. PubMed ID: 18245539
[TBL] [Abstract][Full Text] [Related]
31. Molecular study of a new family with hereditary renal cell carcinoma and a translocation t(3;8)(p13;q24.1).
Meléndez B; Rodríguez-Perales S; Martínez-Delgado B; Otero I; Robledo M; Martínez-Ramírez A; Ruiz-Llorente S; Urioste M; Cigudosa JC; Benítez J
Hum Genet; 2003 Feb; 112(2):178-85. PubMed ID: 12522559
[TBL] [Abstract][Full Text] [Related]
32. Establishment and characterization of a renal cell carcinoma line from a patient with von Hippel-Lindau syndrome.
Morash BA; Lee CL; Rowden G; Riddell DC; Guernsey DL
Cancer Genet Cytogenet; 1997 Jul; 96(1):50-7. PubMed ID: 9209471
[TBL] [Abstract][Full Text] [Related]
33. The epigenetic modifier CHD5 functions as a novel tumor suppressor for renal cell carcinoma and is predominantly inactivated by promoter CpG methylation.
Du Z; Li L; Huang X; Jin J; Huang S; Zhang Q; Tao Q
Oncotarget; 2016 Apr; 7(16):21618-30. PubMed ID: 26943038
[TBL] [Abstract][Full Text] [Related]
34. Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma.
Igarashi H; Esumi M; Ishida H; Okada K
Cancer; 2002 Jul; 95(1):47-53. PubMed ID: 12115316
[TBL] [Abstract][Full Text] [Related]
35. Molecular genetic studies of sporadic and familial renal cell carcinoma.
Gnarra JR; Glenn GM; Latif F; Anglard P; Lerman MI; Zbar B; Linehan WM
Urol Clin North Am; 1993 May; 20(2):207-16. PubMed ID: 8098558
[TBL] [Abstract][Full Text] [Related]
36. CpG dinucleotide-specific hypermethylation of the TNS3 gene promoter in human renal cell carcinoma.
Carter JA; Górecki DC; Mein CA; Ljungberg B; Hafizi S
Epigenetics; 2013 Jul; 8(7):739-47. PubMed ID: 23803643
[TBL] [Abstract][Full Text] [Related]
37. Integrative analysis of dysregulated microRNAs and mRNAs in multiple recurrent synchronized renal tumors from patients with von Hippel-Lindau disease.
Gattolliat CH; Couvé S; Meurice G; Oréar C; Droin N; Chiquet M; Ferlicot S; Verkarre V; Vasiliu V; Molinié V; Méjean A; Dessen P; Giraud S; Bressac-De-Paillerets B; Gardie B; Tean Teh B; Richard S; Gad S
Int J Oncol; 2018 Oct; 53(4):1455-1468. PubMed ID: 30066860
[TBL] [Abstract][Full Text] [Related]
38. The Clinicopathological Significance of Epigenetic Silencing of VHL Promoter and Renal Cell Carcinoma: A Meta-Analysis.
Yang L; Zhao Z; Zhao S; Chen C; Cong X; Li Z; Ren M
Cell Physiol Biochem; 2016; 40(6):1465-1472. PubMed ID: 27997886
[TBL] [Abstract][Full Text] [Related]
39. The VHL-dependent regulation of microRNAs in renal cancer.
Neal CS; Michael MZ; Rawlings LH; Van der Hoek MB; Gleadle JM
BMC Med; 2010 Oct; 8():64. PubMed ID: 20964835
[TBL] [Abstract][Full Text] [Related]
40. Oxidative stress and DNA hypermethylation status in renal cell carcinoma arising in patients on dialysis.
Hori Y; Oda Y; Kiyoshima K; Yamada Y; Nakashima Y; Naito S; Tsuneyoshi M
J Pathol; 2007 Jun; 212(2):218-26. PubMed ID: 17451187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
